| Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ... Journal of Clinical oncology 34 (21), 2460-2467, 2016 | 1544 | 2016 |
| The adenosine pathway in immuno-oncology B Allard, D Allard, L Buisseret, J Stagg Nature Reviews Clinical Oncology 17 (10), 611-629, 2020 | 349 | 2020 |
| Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers T Gruosso, M Gigoux, VSK Manem, N Bertos, D Zuo, I Perlitch, SMI Saleh, ... The Journal of clinical investigation 129 (4), 1785-1800, 2019 | 333 | 2019 |
| CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer C Gu-Trantien, E Migliori, L Buisseret, A de Wind, S Brohée, S Garaud, ... JCI insight 2 (11), 2017 | 305 | 2017 |
| Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer S Garaud, L Buisseret, C Solinas, C Gu-Trantien, A de Wind, ... JCI insight 4 (18), 2019 | 262 | 2019 |
| Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer L Buisseret, S Garaud, A de Wind, G Van den Eynden, A Boisson, ... Oncoimmunology 6 (1), e1257452, 2017 | 224 | 2017 |
| Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial L Buisseret, S Pommey, B Allard, S Garaud, M Bergeron, I Cousineau, ... Annals of oncology 29 (4), 1056-1062, 2018 | 170 | 2018 |
| A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer R Nanda, LQ Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ... San Antonio Breast Cancer Symposium, 9-13, 2014 | 170 | 2014 |
| Targeting immune checkpoints in breast cancer: an update of early results C Solinas, A Gombos, S Latifyan, M Piccart-Gebhart, M Kok, L Buisseret ESMO open 2 (5), e000255, 2017 | 150 | 2017 |
| Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach Y Bareche, L Buisseret, T Gruosso, E Girard, D Venet, F Dupont, ... JNCI: Journal of the National Cancer Institute 112 (7), 708-719, 2020 | 144 | 2020 |
| Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer L Buisseret, C Desmedt, S Garaud, M Fornili, X Wang, G Van den Eyden, ... Modern Pathology 30 (9), 1204-1212, 2017 | 112 | 2017 |
| Immune infiltration in invasive lobular breast cancer C Desmedt, R Salgado, M Fornili, G Pruneri, G Van den Eynden, ... JNCI: Journal of the National Cancer Institute 110 (7), 768-776, 2018 | 108 | 2018 |
| Immunotherapy in breast cancer: an overview of current strategies and perspectives V Debien, A De Caluwé, X Wang, M Piccart-Gebhart, VK Tuohy, ... NPJ Breast Cancer 9 (1), 7, 2023 | 107 | 2023 |
| Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta … C Solinas, M Ceppi, M Lambertini, M Scartozzi, L Buisseret, S Garaud, ... Cancer treatment reviews 57, 8-15, 2017 | 106 | 2017 |
| CD73 promotes resistance to HER2/ErbB2 antibody therapy M Turcotte, D Allard, D Mittal, Y Bareche, L Buisseret, V José, S Pommey, ... Cancer research 77 (20), 5652-5663, 2017 | 104 | 2017 |
| Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer S Garaud, P Zayakin, L Buisseret, U Rulle, K Silina, A De Wind, ... Frontiers in immunology 9, 2660, 2018 | 83 | 2018 |
| Immuno-oncology-101: overview of major concepts and translational perspectives B Allard, S Aspeslagh, S Garaud, FA Dupont, C Solinas, M Kok, B Routy, ... Seminars in cancer biology 52, 1-11, 2018 | 74 | 2018 |
| A simple and rapid protocol to non-enzymatically dissociate fresh human tissues for the analysis of infiltrating lymphocytes S Garaud, C Gu-Trantien, JN Lodewyckx, A Boisson, P De Silva, ... JoVE (Journal of Visualized Experiments), e52392, 2014 | 64 | 2014 |
| PolyI: C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors R Charlebois, B Allard, D Allard, L Buisseret, M Turcotte, S Pommey, ... Cancer research 77 (2), 312-319, 2017 | 44 | 2017 |
| Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer I Nederlof, D De Bortoli, Y Bareche, B Nguyen, M De Maaker, GKJ Hooijer, ... Breast cancer research 21, 1-13, 2019 | 43 | 2019 |
